Skip to main content

Table 2 Results of cox regression analyses by surgical and nonsurgical treatment

From: Conditional survival of pancreatic ductal adenocarcinoma in surgical and nonsurgical patients: a retrospective analysis report from a single institution in China

Factors

Curative resection

Palliative surgery

Nonsurgery

Univariate

Multivariate

Univariate

Multivariate

Univariate

Multivariate

P

HR (95 % CI)

P

P

HR (95 % CI)

P

P

HR (95 % CI)

P

Age (ā‰¤63 v >63)

0.041

Ā 

0.267

0.002

2.064 (1.222ā€“3.485)

0.007

0.719

Ā 

NA

Gender (male v female)

0.604

Ā 

NA

0.411

Ā 

NA

0.178

Ā 

NA

Smoking (yes v no)

0.509

Ā 

NA

0.188

Ā 

NA

0.902

Ā 

NA

Diabete (yes v no)

0.976

Ā 

NA

0.096

Ā 

NA

0.208

Ā 

NA

Alcoholism (yes v no)

0.112

Ā 

NA

0.388

Ā 

NA

0.723

Ā 

NA

Tumor size (ā‰¤2 v >2)

0.014

Ā 

0.467

0.283

Ā 

NA

0.609

Ā 

NA

Tumor number (single v multiple)

0.143

Ā 

NA

0.355

Ā 

NA

0.538

Ā 

NA

Tumor encapsulation (yes v no)

0.208

Ā 

NA

<0.001

3.799 (2.147ā€“6.723)

<0.001

NA

Ā 

NA

Tumor location (head v body/distal/multifocal)

0.116

Ā 

NA

0.017

Ā 

0.088

0.021

Ā 

0.927

Tumor differentiation (Iā€“II v IIIā€“IV)

<0.001

4.082 (2.096ā€“7.952)

<0.001

0.017

Ā 

0.122

NA

Ā 

NA

Lymph nodes positive (yes v no)

0.001

0.395 (0.196ā€“0.798)

0.010

0.005

Ā 

0.307

NA

Ā 

NA

AJCC stage (Iā€“II v IIIā€“IV)

0.010

Ā 

0.764

0.892

Ā 

NA

0.009

1.405 (1.080ā€“1.828)

0.011

CEA (ā‰¤2ULN v >2ULN)

0.013

Ā 

0.078

0.001

3.568 (1.751ā€“7.269)

<0.001

0.006

1.600 (1.054ā€“2.428)

0.027

CA19-9 (ā‰¤2ULN v >2ULN)

0.033

Ā 

0.339

<0.001

Ā 

0.066

0.525

Ā 

NA

Chemotherapy (yes v no)

<0.001

8.050 (2.349ā€“27.591)

0.001

<0.001

13.799 (4.129ā€“45.711)

<0.001

<0.001

5.118 (3.209ā€“8.162)

<0.001

  1. Univariate analysis: Kaplan-Meier method; multivariate analysis: Cox proportional hazards regression model
  2. CR curative resection, IR incurative resection, UR unresection; Tumor differentiation I: Well differentiated; II: moderately differentiated; III: poorly differentiated; and IV: undifferentiated, AJCC American Joint Committee on Cancer staging system, CEA carcinoembryonic antigen; CA19-9 carbohydrate antigen 19-9, NA not adopted